Antisoma Acquires Aptamera
Business Review Editor
Abstract
Antisoma acquired Aptamera in a share-based transaction initially valued at £11.5 M. Through the acquisition of Aptamera’s main asset, anticancer drug AGRO100, Antisoma expands its clinical portfolio.
Full Text: pdf
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.